Clinical trials: Rebound Therapy
COVID-19
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound.
- Trial name
- NCT05567952
- Testing
- nirmatrelvir, ritonavir
- Where
- 84 sites in United States, Canada and 3 more
- Volunteers
- 436 people
- Sponsor
- Pfizer